|
Canada-0-FreightForwarding 公司名錄
|
公司新聞:
- Update on tocilizumab in rheumatoid arthritis: a narrative . . .
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint pain, swelling, and stiffness, affecting approximately 1% of the adult population Tocilizumab (TCZ), a monoclonal antibody targeting the IL-6 receptor, has emerged
- Tocilizumab (Actemra) - American College of Rheumatology
Tocilizumab (Actemra) Tocilizumab (Actemra) is a biologic medication approved to treat adults with moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis complicated by interstitial lung disease, and juvenile idiopathic arthritis among other diseases
- ACTEMRA® (tocilizumab) Rheumatoid Arthritis (RA) Treatment . . .
ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- Tocilizumab (Actemra®) - Johns Hopkins Arthritis Center
Tocilizumab (Actemra®) What is Tocilizumab (Actemra®)? Tocilizumab is in a class of drugs called biologics Tocilizumab is a treatment for adults with moderate to severe rheumatoid arthritis (RA), giant cell arteritis, and polyarticular and systemic juvenile idiopathic arthritis
- Rheumatoid Arthritis (RA) Injections | ACTEMRA® (tocilizumab)
Learn about ACTEMRA® (tocilizumab) injections for Rheumatoid Arthritis (RA) See Full Safety and Boxed Warnings for more information
- Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic . . .
Objective To compare the benefit and safety of tocilizumab to placebo in patients with rheumatoid arthritis (RA) Methods We searched multiple databases for published randomized or controlled clinical trials comparing benefit and safety of tocilizumab to placebo, disease-modifying antirheumatic drugs (DMARD), or other biologics For dichotomous outcomes, we calculated the relative risk, and
- IL-6 inhibitor for the treatment of rheumatoid arthritis: A . . .
Abstract Tocilizumab (TCZ) is an interleukin-6 (IL-6) inhibitor used for the treatment of rheumatoid arthritis (RA) It was developed in 2008, and its effectiveness is supported by evidence from all over the world based on its first decade of use Although the overall efficacy and safety profiles of TCZ are similar to those of tumor necrosis factor (TNF) inhibitors, TCZ displays certain
- Tocilizumab | Arthritis UK
Tocilizumab is a biological therapy for rheumatoid arthritis and juvenile idiopathic arthritis (JIA) Learn how it’s used, risks and side-effects
- Efficacy, safety, and immunogenicity of proposed biosimilar . . .
This phase 3 study (jRCT2031220512) evaluated the equivalence in efficacy, and compared the serum concentration, pharmacodynamics, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in adults with active rheumatoid arthritis (RA)
- Tocilizumab: A Review in Rheumatoid Arthritis - PMC
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor antagonist, are approved (± methotrexate) in numerous countries throughout the world, for the treatment of adults with moderate to severe active rheumatoid arthritis
|
|